Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
236.50
+10.20 (4.51%)
At close: Oct 15, 2026, 4:00 PM EDT
235.76
-0.74 (-0.31%)
After-hours: Oct 15, 2026, 4:47 PM EDT
Moderna Revenue
Moderna had revenue of $145.00M in the quarter ending June 30, 2026, with 2.11% growth. This brings the company's revenue in the last twelve months to $2.23B, down -27.62% year-over-year. In the year 2025, Moderna had annual revenue of $1.94B, down -39.93%. That makes Moderna the 4,631st largest company in the world by revenue and 1,236th in the United States.
Revenue (ttm)
$2.23B
Revenue Growth
-27.62%
P/S Ratio
42.38
Revenue / Employee
$474,043
Employees
4,700
Market Cap
94.42B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.94B | -1.29B | -39.93% |
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | 60.00M | -75.07M | -55.58% |
| Dec 31, 2018 | 135.07M | -70.76M | -34.38% |
| Dec 31, 2017 | 205.83M | 97.43M | 89.88% |
| Dec 31, 2016 | 108.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 15.53B |
| Vertex Pharmaceuticals | 12.59B |
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
MRNA News
- 46 minutes ago - Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches - TipRanks
- 10 hours ago - Moderna price target raised to $137 from $120 at Goldman Sachs - TheFly
- 1 day ago - Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make - CNBC
- 2 days ago - Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry - WSJ
- 2 days ago - FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban - Business Insider
- 2 days ago - ‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks - Market Watch
- 2 days ago - Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 - Accesswire
- 3 days ago - Moderna call buyer realizes 173% same-day gains - TheFly